Global Medication Assisted (MAT) Treatment Market - Industry Trends and Forecast to 2029

Segmentation

Short Description
Global Medication-Assisted Treatment (MAT) Market, By Type (Medication and Therapy), Products (Buprenorphine and Naloxone, Naltrexone, Buprenorphine, Methadone, Naloxone, Disulfiram, and Acamprosate), Drug Type (Generics and Branded), Dosage Form (Immediate Release and  Extended Release), Route of Administration (Oral, Parenteral, and Others), Population Type (Adults and Teenage), End User (Rehabilitation Clinics, Hospitals, Specialty Centres, Homecare, and Others) Distribution Channel (Hospital Pharmacy, Direct Tender, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, Norway, Poland, Hungary, Lithuania, Austria, Ireland and Rest of Europe, China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific, South Africa, Saudi Arabia, UAE, Egypt, Israel, Kuwait and Rest of Middle East and Africa U.S., Canada, and Mexico and Rest of North America) Industry Trends and Forecast to 2029


Market Definition:

Medication-assisted treatment (MAT), involves the use of medications, combined with counseling and behavioral therapies, to provide a complete patient approach for treating substance use disorders. MAT is primarily used to treat addiction to opioids such as heroin and prescription pain relievers. The aim of MAT is proper recovery, which includes improved patient survival, increased treatment retention, reduced illicit response, and grow in pregnancy outcomes among women.
The Food and Drug Administration (FDA) approved three drugs for clinical use which are buprenorphine, methadone, and naltrexone. Medication-assisted treatment (MAT) is applied to cure alcohol use disorder, opioid dependency medication, and opioid overdose prevention medication. Alcohol use disorder (AUD) is a medical condition characterized by an impaired ability to stop alcohol use despite adverse social, occupational, or health consequences. Acamprosate, disulfiram, and naltrexone are the most common medications used to treat alcohol use disorder (AUD). The opioid dependency medication, rise in addiction for opioids among patients. Buprenorphine, methadone and naltrexone are used to treat opioid use disorders to short-acting opioids such as heroin, morphine, and codeine, as well as semi-synthetic opioids like oxycodone and hydrocodone. These MAT medications are safe for months, years, or even a lifetime. For opioid overdose prevention medication, naloxone is used to prevent opioid overdose by reversing the toxic effects of the overdose. According to the World Health Organization (WHO) and by Substance Abuse and Mental Health Services Administration (SAMHSA), naloxone is one of many medications considered essential to a functioning health care system.
Market Segmentation:
The global medication-assisted treatment (MAT) market is categorized into eight segments: type, products, drug type, dosage form, route of administration, population type, end user, and distribution channel.

 On the basis of type, the global medication-assisted treatment (MAT) market is segmented into medication and therapy
 On the basis of product, the global medication-assisted treatment (MAT) market is segmented into buprenorphine and naloxone, naltrexone, buprenorphine, acamprosate, methadone, naloxone, and disulfiram
 On the basis of drug type, the global medication-assisted treatment (MAT) market is segmented into branded and generics
 On the basis of dosage form, the global medication-assisted treatment (MAT) market is segmented into extended-release and immediate-release
 On the basis of route of administration, the global medication-assisted treatment (MAT) market is segmented into oral, parenteral, and others
 On the basis of population type, the global medication-assisted treatment (MAT) market is segmented into children and teenage
 On the basis of end user, the global medication-assisted treatment (MAT) market is segmented into rehabilitation clinics, hospitals, specialty centers, homecare, and others
 On the basis of distribution channel, the global medication-assisted treatment (MAT) market is segmented into direct tender hospital pharmacy, retail pharmacy, online pharmacy, and others

Market Players

Some of the major players operating in the global medication-assisted treatment (MAT) market are:

 Indivior PLC
 Orexo US Inc (a subsidiary of Orexo AB)
 Recovery Centers of America
 Alkermes.
 Sun Pharmaceutical Industries Ltd.
 Purdue Pharma L.P.
 Taj Pharmaceuticals Limited
 Lannett
 Hikma Pharmaceuticals PLC
 Pfizer Inc.
 Pinnacle Treatment Center
 American Addiction Centers
 Adamis Pharmaceuticals Corporation
 Glenmark Pharmaceutical Inc.
 Viatris Inc.
 Mallinckrodt
 Alvogen
 Accord Healthcare
 VistaPharm, Inc.
 Teva Pharmaceutical Industries Ltd.
 Dr. Reddys Laboratories Ltd.
 Amneal Pharmaceuticals LLC.
 Titan Pharmaceuticals, Inc.

Methodology